Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Clin Cancer Res. 2017 Jun 9;23(17):5281–5291. doi: 10.1158/1078-0432.CCR-17-0171

Figure 6.

Figure 6

IL17RD mediates the impact of miR-193a-3p on tumor growth and EGFR signaling A) Western blots demonstrating protein expression following transfection with the indicated doses of miR-193a-3p or a scrambled probe in HCT116 cells stably transfected with a vector containing IL17RD with wildtype 3’UTR or IL17RD with mutant 3’UTR. Images represent one of two blots using the same conditions B) Quantitation of protein expression following transfection with the indicated doses of miR-193a-3p or a scrambled probe in HCT116 cells stably transfected with a vector containing IL17RD with wildtype 3’UTR or IL17RD with mutant 3’UTR. *p<0.05. C) Western blots demonstrating protein expression in parental HCT116 cells (par) or following treatment with a scrambled probe or miR-193a-3p inhibitor (Inh) at the indicated doses in HCT116 cells stably transfected with a vector containing IL17RD with wildtype 3’UTR or IL17RD with mutant 3’UTR. Images represent one of two blots using the same conditions D) Quantitation of protein expression following transfection with the indicated doses of a miR-193a-3p antagomir or a scrambled probe in HCT116 cells stably transfected with a vector containing IL17RD with wildtype 3’UTR or IL17RD with mutant 3’UTR. *p<0.05. E) Time course of tumor growth of HCT116 cells stably transfected with a vector coding for IL17RD with wildtype 3’UTR or mutant 3’UTR with mutations in the seed binding sites for IL17RD and treated with intraperitoneal injection of miR-193a-3p (n=10 mice containing one cell line in each flank) or vehicle (n=5). F) Representative images of ki67 staining of tumor xenografts of cells expressing IL17RD with wild type or mutant 3’UTR in mice treated with miR-193a-3p. G) Quantification of KI67 staining from tumors consisting of HCT116 cells expressing IL17RD with wild-type 3’UTR. Mice were treated with miR-193a-3p or vehicle as indicated (n=5/group). H) Tumor volume by day in tumor xenografts containing HCT116 cells stably transfected with a vector containing IL17RD and a wildtype 3’UTR treated with intraperitoneal injection of anti-miR-193a-3p (n=9) or vehicle (n=6).